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ABSTRACT
Introduction: Recognising a tumour predisposition
syndrome (TPS) in patients with childhood cancer is of
significant clinical relevance, as it affects treatment,
prognosis and facilitates genetic counselling. Previous
studies revealed that only half of the known TPSs are
recognised during standard paediatric cancer care. In
current medical practice it is impossible to refer every
patient with childhood cancer to a clinical geneticist,
due to limited capacity for routine genetic consultation.
Therefore, we have developed a screening instrument
to identify patients with childhood cancer with a high
probability of having a TPS. The aim of this study is to
validate the clinical screening instrument for TPS in
patients with childhood cancer.
Methods and analysis: This study is a prospective
nationwide cohort study including all newly diagnosed
patients with childhood cancer in the Netherlands.
The screening instrument consists of a checklist,
two- and three-dimensional photographic series of the
patient. 2 independent clinical geneticists will assess
the content of the screening instrument. If a TPS is
suspected based on the instrument data and thus
further evaluation is indicated, the patient will be
invited for full genetic consultation. A negative control
group consists of 20% of the patients in whom a TPS
is not suspected based on the instrument; they will be
randomly invited for full genetic consultation. Primary
outcome measurement will be sensitivity of the
instrument.
Ethics and dissemination: The Medical Ethical
Committee of the Academic Medical Centre stated that
the Medical Research Involving Human Subjects Act
does not apply to this study and that official approval
of this study by the Committee was not required. The
results will be offered for publication in peer-reviewed
journals and presented at International Conferences on
Oncology and Clinical Genetics. The clinical data
gathered in this study will be available for all
participating centres.
Trial registration number: NTR5605.
INTRODUCTION
It is of signiﬁcant clinical relevance to recog-
nise a tumour predisposition syndrome
(TPS). It may lead to (1) recognition of
other signs and symptoms unrelated to
cancer, (2) affect treatment, (3) allow suit-
able cancer surveillance strategies, (4) offer
insights into the prognosis of the child, and
(5) can facilitate adequate genetic counsel-
ling of the child and its family members.
Two large cohort studies reported that
7.2–8.5 per cent of patients who develop
cancer as a child, have a TPS.1 2 Research in
the Netherlands in a large series of children
with cancer showed that half of the TPSs
were not recognised by the physicians
involved in the daily care of the child with
cancer.1
It has been proposed that all children with
cancer should be examined by a physician
familiar with dysmorphology and cancer pre-
disposition, preferably by a clinical geneti-
cist.3 4 However, referring all patients with
childhood cancer for genetic evaluation is
impossible in current clinical practice due to
Strengths and limitations of this study
▪ Nationwide study.
▪ Systematically gathering of clinical and pheno-
typic information and DNA samples of patients
with childhood cancer.
▪ Focus on validation of the screening instrument
in Dutch medical practice only, feasibility of the
screening instrument in other (non-Western
World) countries remains unstudied.
▪ No molecular genetic studies were performed,
only gathering of samples for molecular studies.
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limited capacity and can be of low priority in acutely ill
patients.
We propose to implement an easy-to-use screening
instrument that can be used in all patients with child-
hood cancer to facilitate detection of patients at risk for
having a TPS. Using the instrument, the clinical geneti-
cist can remotely review the patient for suspicion for a
TPS and thus determine the need for referral for a full
clinical genetic evaluation. The screening instrument
should guarantee that the presence of a TPS is
adequately evaluated in each child with cancer. Such a
screening instrument should be easy to execute by a
research nurse, genetic counsellor or treating physician.
The screening instrument should be based on the mor-
phological abnormalities (manifestations) of known
TPSs, as these manifestations have been shown to indi-
cate cancer susceptibility.1 3 5 Part of the manifesta-
tions of TPSs will be visible on two-dimensional (2D)
and three-dimensional (3D) photographs. This will
support remote evaluation of detailed morphological
characteristics of the patient by a clinical geneticist, and
enable discussion with colleagues if desired. However,
not all manifestations will be visible in these photo-
graphs. Therefore, we have recently identiﬁed the most
important and sensitive manifestations of known TPSs
that are not detectable on such photographs. This list of
47 speciﬁc manifestations was composed following a
two-round Delphi process with eight international
content-speciﬁc experts.6 Subsequently, we have devel-
oped the screening instrument, consisting of the 2D and
3D photographic series complemented by a childhood
cancer syndrome checklist (CCSC, see online
supplementary appendix 1) listing the selected manifes-
tations not visible on this set of photographs completed
with patient characteristics and family history.
In 2016, Jongmans et al7 developed a selection tool
based on the literature and expert opinion/empirical
data, designed to support paediatric oncologists in their
choice to refer a patient for clinical consultation or not.
Since the concept and methodology of the selection tool
described by Jongmans et al and our screening instru-
ment differ markedly, parallel validation is not possible
as it would interfere with the current study methodology.
Study aim
The primary aim of the Validation of a clinical screening
instrument for tumour predisposition syndromes in patients
with childhood cancer (TuPS) study is to assess the clinical
validity of the screening instrument in identifying
patients with childhood cancer at risk for a TPS from a
non-selected prospective cohort of patients with child-
hood cancer. We hypothesise that the screening instru-
ment will be equivalent to or better than the current
practice in recognising patients with a TPS and we
assume high sensitivity (94%), and therefore being gen-
erally accepted as clinically relevant.
The secondary aim of the TuPS study is to identify
(patterns of) morphological abnormalities in a patient
with childhood cancer with predictive value by using 3D
facial analysis to improve the screening instrument.
Improvement of diagnostic value due to implementation
of speciﬁc morphological abnormalities will be
expressed in terms of effect on sensitivity of the screen-
ing instrument. We hypothesise that we will ﬁnd signiﬁ-
cant differences in facial phenotypes unrelated to
therapy between patients with childhood cancer and
their healthy peers.
METHODS AND ANALYSIS
Study design
TuPS is a prospective, observational, nationwide, multi-
centre patient cohort study. Eligible consecutive patients
with childhood cancer will be included after informed
consent has been obtained from their parents (and
themselves if 12 years or older), according to the
current Dutch ethical regulations.
Study flow
The study ﬂow is depicted in ﬁgure 1. After written
consent, the patient will be seen by the local genetic
counsellor or research nurse who will give the patient a
coded study number. The study numbers are centrally
supplied by the study coordinator. The genetic counsel-
lor/research nurse will complete the CCSC. In addition,
2D and 3D digital photographs will be taken by the local
medical photographer. The data gathered (CCSC and
photographic series) will be uploaded in a central data-
base and presented electronically to two independent
clinical geneticists from centres different from the
patient’s centre. The two clinical geneticists will assess
the content of the screening instrument, by answering a
short questionnaire (table 1).
Patients in whom a TPS is suspected by one or both
clinical geneticists (ie, a positive screening result) will be
referred for full genetic consultation in the patient’s
own treatment centre (‘gold standard’). Note that the
local clinical geneticist who will perform the full genetic
consultation will be different from the independent clin-
ical geneticists performing the digital assessment of the
same patient using the screening instrument. Patients in
whom a TPS is not suspected by both clinical geneticists
(ie, a negative screening result) will randomly be invited
to follow full genetic consultation as well. This random-
isation will be carried out by the study coordinator in
1:5 ratio, using the online randomisation database ALEA
(ALEA software, TenALEA consortium, Amsterdam, The
Netherlands). The evaluation of any child with cancer is
part of standard patient care, and the referral of these
children is therefore also part of normal care and costs
are covered by the health insurances. The local clinical
geneticist, referred patients and their parents are
blinded to the result of the digital assessment of the
screening instrument.
Molecular conﬁrmation of suggested clinical diagnoses
is not part of the study design. Study participants in
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whom a clinical diagnosis is suspected will be referred
for routine patient care studies to the clinical geneticist.
In the Netherlands a clinical diagnosis is invariably con-
ﬁrmed by molecular testing if this is available for the
entity involved.
The results of the full genetic consultation will be allo-
cated to one of three categories: conﬁrmed TPS; no
TPS; and a private syndrome, deﬁned as strong suspi-
cion of a TPS based on medical history, physical signs
and symptoms but not ﬁtting a recognisable pattern of a
known TPS. We will classify a conﬁrmed TPS on clinical
grounds, which should be conﬁrmed by an appropriate
metabolic, cytogenetic, or molecular test whenever pos-
sible. The trial will be reported according to the
Consolidated Standards of Reporting Trials
(CONSORT) guidelines as far as applicable.
Study setting
The study is to be carried out in all six paediatric oncol-
ogy centres and their allied clinical genetic departments,
in the Netherlands: Emma Children’s Hospital/
Academic Medical Centre Amsterdam, VU University
Medical Centre Amsterdam, Sophia Children’s Hospital/
Erasmus Medical Centre Rotterdam, Princess Máxima
Centre for Paediatric Oncology/University Medical
Centre Utrecht, Beatrix Children’s Hospital/University
Medical Centre Groningen, Radboud University Medical
Centre Nijmegen. The recruitment period will be 2 years,
starting from January 2016.
Screening instrument
Childhood cancer syndrome checklist
The CCSC consists of patient characteristics (history,
tumour type and development), family history and 47
selected speciﬁc physical manifestations which may not
be detectable on 2D and 3D photographs (see online
supplementary appendix 1).6
Generally, the CCSC will be completed by a genetic
counsellor or a research nurse. If this is not possible,
any person with sufﬁcient medical background, but
without explicit knowledge on TPSs, may do so. The
genetic counsellor/research nurse will receive a booklet
that has been developed speciﬁcally for this study,
showing deﬁnitions for the 47 speciﬁc manifestations
(not visible on photographs, selected using Delphi as
described in the Introduction section) to be aware of
during physical examination.
2D and 3D photographic series
In this study, only the patient will be photographed. The
photographic series consists of 2D photograph of the
face (front portrait and proﬁle), hands, feet and skin
and one 3D photograph of the face. The photographs
allow for repeated measurements, close inspection with
minimal intrusion and without requiring prolonged
cooperation of the patient. Using 3D models, the
average shape of a collection of faces can be computed,
quantitative shape comparisons of face surfaces can be
Figure 1 Study flow. 2D, two-dimensional; 3D, three-
dimensional; CCSC, childhood cancer syndrome checklist;
TPS, tumour predisposition syndrome.
Table 1 Questionnaire for decision of clinical geneticist
using screening instrument
1. Is there for this patient any reason for referral to a
clinical geneticist for further examination into the
suspicion of the presence of a TPS?
If no: end questionnaire
2. Based on what is your decision made? (Multiple
answers possible)
□ The type of malignancy
□ Medical history of the patient
□ Family history
□ Morphological abnormality as depicted on the
childhood cancer checklist
□ Morphology 2D pictures
□ Morphology 3D picture
3. Would you refer the patient if you did not have the
access to the 2D and 3D pictures?
If no:
○ My referral was mainly based on the 2D pictures
○ My referral was mainly based on the 3D picture
○ My referral was mainly based on both the 2D and
3D pictures
2D, two-dimensional; 3D, three-dimensional; TPS, tumour
predisposition syndrome.
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performed and face shape of a patient can be normal-
ised with respect to ethnicity, age and sex matched
mean.8 The photographs will be taken by the local
(trained) medical photographer, using their own 2D
camera and a centrally provided 3D camera: the
VECTRA M3 Imaging System, manufactured by Canﬁeld
Scientiﬁc (http://www.canﬁeldsci.com).
Decision support scheme
Two independent clinical geneticists will be invited to
assess the content of the screening instrument (CCSC
and photographic series) electronically, by means of the
decision support scheme. The decision support
scheme is a preassembled document, approved by all
participating clinical geneticists of the six centres (see
online supplementary appendix 2). It states when a
patient should be referred to a clinical geneticist for
complete genetic consultation. It consists of four parts;
questions on malignancy, medical history, family history
and morphological examination. The clinical geneticists
are blinded to each other’s assessment.
Malignancy: A comprehensive search in PubMed was
carried out. The purpose of this search was to provide
an overview of the literature on the likelihood of the
presence of a TPS per type of malignancy in children.
Subsequently, the results for malignancy-driven referral
for genetic evaluation for TPSs in childhood cancer
have been discussed during a Dutch nationwide
meeting until consensus was reached. These results
will be offered for publication (Postema et al, in
preparation).
Medical history: Various aspects of the medical history
of the patient can lead to referral to a clinical geneticist.
According to expert opinion and the consensus meeting
these aspects include: previous primary cancers, learning
and developmental problems, growth problems or spe-
ciﬁc other medical problems in the context of a TPS,
such as immunodeﬁciency or organ malformations/
dysfunction.
Family history: According to expert opinion and the
consensus meeting, referral to a clinical geneticist
should be considered when cancer occurs in family
members up to the third degree.
Morphological examination: Morphological abnormalities
may be noticed using the CCSC as described above, or
on the 2D and 3D photographic series.
Patients
Criteria
All patients with childhood cancer in the Netherlands
seen by a paediatric oncologist during the study period
will be screened for eligibility. The inclusion criteria for
enrolment of patients are: (1) age 0–18 years; and (2) a
newly diagnosed malignancy. Patients are excluded if
they have already been diagnosed with a syndrome
known to be associated with the current observed
malignancy.
Sample size
This study is the ﬁrst to assess the clinical value of a newly
developed screening instrument in a national childhood
cancer population that includes all types of malignancies.
Therefore, the sample size calculation is based on 7.2%
as the minimal prevalence of a TPS in patients with child-
hood cancer, based on the results of the study of Merks
et al.1 This might be an underestimate because the major-
ity of patients included in this published study were survi-
vors; the incidence of TPSs in survivors might be low due
to the negative inﬂuence of some TPSs on survival.1 Next
to that, TPSs without malformations, such as the
Li-Fraumeni syndrome have not been identiﬁed in this
clinical morphological examination study.
The incidence of childhood cancer, based on histor-
ical annual reports of the Dutch Childhood Oncology
Group (DCOG) was estimated as 550 newly diagnosed
patients per year.
For a screening instrument to be clinically relevant, we
assumed a sensitivity of 94% or higher to be acceptable.
Since speciﬁcity is unknown, we used an assumed speciﬁ-
city of 50% in our power calculations. For power calcula-
tions, we followed the methodology described by Jones
et al.9
Using these assumptions associated with the study
design (prevalence 7.2%, sensitivity 94% and speciﬁcity
50%), we expect to ﬁnd 532 patients with a positive
screening result in a theoretical cohort of 1000 evaluable
individuals (table 2). We expect to ﬁnd 468 individuals
with a negative screening result. From this group, 20%
are evaluated to determine the number of false nega-
tives. Under these conditions, we are allowed to ﬁnd a
maximum of one false-negative individual in the 20%
sample. If this holds true we can conclude that 98.9%
(CI 94.2 to 99.8) of negatively screened individuals are
indeed true negatives. In this scenario, we would need a
group of 626 patients (532 patients with a positive
screening and 94 patients selected for random sample
ie, 20% of 468 patients with a negative screening result)
who are seen by a clinical geneticist for a standard
genetic consultation. Based on prior experience, we
expect a 90% participation rate and an extremely low
frequency of drop outs (including study withdrawal).
Owing to this expected low frequency of drop outs,
these are not included in the calculations.
Withdrawal of individual patients
Patients can withdraw from the study at any time,
without giving reasons. Data and samples already
Table 2 2×2 Table sample size calculations
TPS+ TPS−
Screening+ 68 464 532
Screening− 4 464 468
72 928 1000
TPS, tumour predisposition syndrome.
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registered can be analysed unless the patient and/or
parent(s) decide otherwise.
Primary and secondary outcomes
Objective 1: validation of the screening instrument
The primary outcome measurement for aim 1 (valid-
ation of the screening instrument) is sensitivity of the
screening instrument. The screening instrument should
have a high sensitivity, as we do not want to miss patients
with a potential TPS. True-positive patients are deﬁned
as patients with a positive screening result and in whom
presence of a TPS or the presence of a private syndrome
was conﬁrmed in full clinical genetic consultation.
False-negative patients are deﬁned as patients with a
negative screening result, in whom presence of a TPS or
the presence of a private syndrome was conﬁrmed in
full clinical genetic consultation.
For the analysis of speciﬁcity, positive and negative pre-
dictive value, we deﬁne false positive patients as patients
with positive screening results in whom no TPS could be
conﬁrmed in full clinical genetic consultation and true
negative cases as patients with a negative screening
result, randomised in the 20% control group, in whom
no TPS could be conﬁrmed in full clinical genetic
consultation.
Interobserver variability will be assessed. Also, individ-
ual attribution of the CCSC and (2D and 3D) photo-
graphic series to the conclusion of the assessment a
clinical geneticist will be a secondary outcome measure-
ment. In addition to that, we will study a subset of patients
in a blinded study based on either morphology on the 3D
photograph or results of the complete screening instru-
ment (also including 2D photographs and CCSC).
A ﬁnal secondary outcome measurement is the differ-
ence in healthcare-related costs of the diagnostic process
using the instrument compared with current standard
clinical genetic care. All costs in total, and costs divided
according to the various parts of the screening instru-
ment, will be calculated.
Objective 2: identifying morphological abnormalities
Shape-related differences in facial morphology (deter-
mined with 3D photograph) between patients with child-
hood cancer and their healthy peers will be expressed in
colour-coded heat maps and signature graphs.
Anthropometric distances using landmark calculations
will be used to further illustrate observed differences as
found in shape analyses.
Clinical data collection
Data on patient characteristics are collected during the
ﬁrst meeting with the genetic counsellor/research
nurse, including month and year of birth; sex; ethnic
background; oncological diagnosis and treatment.
Furthermore, data are collected on the clinical history of
the patient, including the pregnancy; development and
family history. Finally, data on physical examination are
collected, including anthropometric data (see online
supplementary appendix 1). For a ﬂow diagram of the
clinical data collection see ﬁgure 2.
The genetic counsellor/research nurse will enter the
CCSC outcomes to the corresponding electronic case
report form (eCRF) in the online database
OpenClinica, V.3.6,10 and upload the photographic
series to the online database XNAT, V.1.6.4.11 The two
clinical geneticists will receive an Excel ﬁle, with the
imported data from OpenClinica, a protected link to the
XNAT website, and a short questionnaire. After the ques-
tionnaire is completed, the clinical geneticist will return
the Excel ﬁle to the study coordinator, who will ﬁll in
the corresponding eCRF in OpenClinica. To ensure
complete independence between the two clinical geneti-
cists, it is not possible for the clinical geneticists to enter
their result directly in OpenClinica, where they would
be able to see each other’s assessment.
After the full genetic consultation, the result of the
consultation will be sent to the study coordinator, who
will enter the result in the corresponding eCRF in
OpenClinica. The data of the results of the assessment
of the two clinical geneticist and the coded results of the
routine genetic consultation will be visually checked by a
second investigator, in order to ensure data integrity.
Data analysis and general statistic considerations
Clinical study data
Descriptive statistics will be performed (cross-tabulation,
frequencies for positive and negative screening results).
Continuous normally distributed variables will be
Figure 2 Flow diagram of clinical data collection. 2D,
two-dimensional; 3D, three-dimensional; CCSC, childhood
cancer syndrome checklist.
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expressed by their mean and SD, or if not normally dis-
tributed, as medians and their IQRs. Categorical vari-
ables will be expressed as counts (n) and percentages
(%). From these data, the sensitivity, speciﬁcity, positive
and negative predictive value of the screening instru-
ment will be deduced. For the interobserver variability
we will use a Fleiss’ κ score. For these calculations, study
data will be exported to IBM SPSS Statistics V.22.
3D analyses
To illustrate the differences in facial phenotype of
patients with childhood cancer in comparison with
healthy controls,12 both shape-related and anthropomet-
ric analyses will be performed. To determine any differ-
ence of importance in morphology between patients
and controls, patient’s face shape data will be normal-
ised to sex-matched, age-matched and ethnicity-matched
controls, and expressed in colour-coded heat maps visua-
lising regional differences. Positive predictive value of
morphological abnormalities will be calculated using
univariate analysis. For morphological abnormalities
with a high-positive predictive value, effect on the sensi-
tivity of the screening instrument will be modelled using
multivariate analysis. The control groups for Caucasian
children, matched for sex and age are already available
for the 3D analyses. For other ethnic groups, the control
groups are at present limited but are rapidly expanding,
and likely sufﬁcient numbers will be available at the end
of the study period.12
Furthermore, anthropometric distances using land-
mark calculations will be used to further illustrate
observed differences as found in shape analyses, as they
are demonstrated to be reliable and reproducible.13 14
Differences in anthropometric distances between
patients and controls will be calculated using Student’s
t-tests, in presence of a normal distribution.
In addition, by comparing original face surfaces to
their reﬂected form, we can study asymmetry and investi-
gate if there is greater facial asymmetry in the patient
group compared with controls. In the 3D analyses, we
will make use of surface shape differences not detectable
by simple linear or angular characteristics as might be
used in analyses based on measures captured manually
or derived from landmarks annotating 2D photographic
images. That way we will use 3D morphometric analysis
in this heterogeneous patient group to further delineate
face shape differences that are too subtle or geometric-
ally complex to identify or quantify objectively with con-
ventional clinical and anthropometric approaches. The
methodology of the 3D analyses is described in detail
elsewhere.8
Finally, one can demonstrate in so called ‘signature’
graphs the similarity between patients in terms of devi-
ation from the average for speciﬁc regions of the face or
when appreciating the facial morphology from a speciﬁc
axis. This way one can use 3D analysis to determine new
patterns of morphological abnormalities that cannot be
distinguished by the naked eye. These applications of
3D analysis are further illustrated by Hammond and
Suttie8 and Hopman et al.15
Biobank
In addition to the validation of the screening instrument,
we have created a biobank in cooperation with DCOG.
We will ask all recruited patients to provide a blood
sample during one of the regular blood tests undertaken
for patient care. DNA will be extracted, and stored in a
central biobank at DCOG. The DNA is intended for
future scientiﬁc research into the aetiology of childhood
cancer. All data will be coded and stored for 15 years.
ETHICS AND DISSEMINATION
Ethics
The Medical Ethical Committee of the Academic
Medical Centre (Amsterdam, the Netherlands) stated
that the Medical Research Involving Human Subjects
Act (WMO) does not apply to the TuPS study and that
ofﬁcial approval of this study by the Committee was not
required (W14_251 #14.17.0303 10-09-2015). The
Biobanking Committee of the Academic Medical Centre
approved the biobank procedure described above
(2015_133#A2015103 02-11-2015).
Consent
Patients newly diagnosed with a childhood malignancy
and their parents will be informed by their paediatric
oncologist, who will supply them with written informa-
tion on all relevant aspects of the TuPS study including
separate information on participation in the biobank
procedure. When the patient is younger than 12 years,
correspondence is directed to the parent(s) or guardian
(s). When the patient is between 12 and 18 years, corres-
pondence is directed to both the patients and their
parent(s) or guardian(s). Written informed consent will
be given by patient and parents when 12 years or older,
by parents alone when the patient is younger than
12 years.
The informed consent forms for participation in the
TuPS study and the biobanking part are separated.
Privacy
The online databases OpenClinica, XNAT and ALEA are
only accessible with assigned log in credentials.
Personal data of participating patients will be strictly
separated from the study data. The genetic counsellor/
research nurse of each participating site has the encryp-
tion key for the coded patient number and has access to
the personal data of the enrolled patients in their own
centre.
The encryption key is only accessible for the principal
investigator and the executive researcher.
Dissemination
After ﬁnalisation of the project, all information gathered
in this study, with the exception of the photographs, will
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be stored at DCOG. The 2D and 3D photographic series
will be stored at the AMC. The coded data is accessible
for all the participating centres. The DCOG research
committee complemented by the chair of the DCOG
task force on childhood oncogenetics will assess add-
itional requests to use the information gathered by the
study.
The encryption key from the six centres will be com-
bined and stored at an independent location, supervised
by the principal investigator.
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